The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines
A. J. Ohnmacht, G. Avar, M. K. Schübel, T. J. O'Neill, D. Krappmann, M. P. Menden
The paper assesses molecular EMT signatures in cancer cell lines to identify drug susceptibilities, showing EMT can predict responses to HSP90 inhibitors and enhance drug sensitivity through TGF-β stimulation.
bioRxiv · Jan 16, 2024 · PreprintCancer Biology